Journal of Clinical Oncology, Vol 15, 2288-2295, Copyright © 1997 by American Society of Clinical Oncology
Engraftment and molecular monitoring of CD34+ peripheral-blood stem- cell transplants for follicular lymphoma: a pilot study
IG McQuaker, AP Haynes, S Anderson, C Stainer, RG Owen, GJ Morgan, M Lumley, D Milligan, J Fletcher, EM Bessell, JM Davis and NH Russell
Department of Hematology, Nottingham City Hospital, United Kingdom.
PURPOSE: A pilot study to validate the use of CD34+ selection (Ceprate SC)
of blood stem-cell collection in patients with advanced follicular lymphoma
receiving myeloablative chemoradiotherapy. PATIENTS AND METHODS: Seventeen
patients were entered onto the protocol. Thirteen of 17 patients have
undergone transplantation; the median age is 42.5 years (range, 33 to 51),
seven of 13 are stage IVB, two stage IVA, three stage IIIB, and one stage
IIB. All except two patients were treated after first or subsequent
relapses after receiving cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) chemotherapy to achieve a good partial (six of 13) or
complete (seven of 13) response before stem-cell mobilization with
cyclophosphamide 3 g/m2 and filgrastim 300 microg once daily. RESULTS:
Eleven of 13 patients had a detectable t(14;18) by nested polymerase chain
reaction (PCR). Median CD34+ count before selection was 2.9 x 10(6)/kg
(range, 1.17 to 11.3) and after CD34+ selection was 1.54 x 10(6)/kg (range,
0.88 to 7.6) with a median CD34+ yield of 62.4% (range, 17% to 95%) and
purity of 60% (range, 39.3% to 73%). Of the 11 patients known to have
t(14;18), 10 had PCR-detectable contamination of stem-cell harvests that
became PCR negative in six of the 10 after CD34+ selection. Engraftment was
rapid with a median day to absolute neutrophil count (ANC) greater than 0.5
x 10(9)/L of 13 days (range, 11 to 21) and platelet count greater than 20 x
10(9)/L of 14 days (range, 10 to 44). With a median follow-up duration of
15 months, three patients have remained persistently PCR-positive, two of
whom received PCR-positive stem cells. Two have relapsed. Of the seven
patients who received PCR- negative stem cells, five have had no
PCR-detectable disease in posttransplant bone marrow samples. CONCLUSION:
Longer follow-up duration is required to determine the significance of
these findings, but we have confirmed the feasibility of CD34+ selected
cells to deplete peripheral-blood stem cells of tumor cells from patients
undergoing high-dose therapy for follicular lymphoma.
This article has been cited by other articles:
|
|
|
|
 
M. Witzens-Harig, C. Heilmann, M. Hensel, M. Kornacker, A. Benner, R. Haas, S. Fruehauf, and A. D. Ho
Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34+-Selected Peripheral Blood Progenitor Cells
Stem Cells,
January 1, 2007;
25(1):
228 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Deconinck, C. Foussard, N. Milpied, P. Bertrand, P. Michenet, P. Cornillet-LeFebvre, M. Escoffre-Barbe, H. Maisonneuve, V. Delwail, R. Gressin, et al.
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS
Blood,
May 15, 2005;
105(10):
3817 - 3823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Bierman, J. W. Sweetenham, F. R. Loberiza Jr, G. Taghipour, H. M. Lazarus, J. D. Rizzo, N. Schmitz, K. van Besien, J. M. Vose, M. Horowitz, et al.
Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
October 15, 2003;
21(20):
3744 - 3753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood,
July 30, 2002;
100(4):
1141 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Holmberg, M. Boeckh, H. Hooper, W. Leisenring, S. Rowley, S. Heimfeld, O. Press, D. G. Maloney, P. McSweeney, L. Corey, et al.
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation
Blood,
December 15, 1999;
94(12):
4029 - 4035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
